The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs at the National Cancer Institute (NCI) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for the development of prophylactic, therapeutic and diagnostic for Coronavirus Disease 2019 (COVID-19). We encourage applications from small businesses with NCI-funded active SBIR/STTR awards for technologies that have a strong potential to be adapted/repurposed for use as a prophylactic, therapeutic or diagnostic tool for SARS-CoV-2 (COVID-19).
A compelling rationale should be presented and linked to an appropriate research plan to generate data in support of the new proposed use. Areas of interest include but not limited to:
Adapting the use of cancer diagnostics and diagnostic technologies and platforms for diagnosing the virus, infection, and potential immunity against the virus rapidly at the point of care setting;
Repurposing or expanding use of cancer vaccines, vaccine candidates, and other technologies for prevention of, and/or protection from SARS-CoV-2 infection;
Repurposing or expanding the use of cancer therapeutics and therapeutic candidates for the treatment of COVID-19 and the management of severe symptoms.
Applicants are strongly encouraged to contact the NCI Program Director of the parent award to discuss potential applications and whether urgent competitive revision applications or administrative supplement requests are more appropriate for the proposed research.
The NCI SBIR program will consider awards of up to $250,000 in total cost for phase I (R43), and $1,000,000 in total cost for phase II (R44). The NCI STTR program will consider awards of up to $250,000 for phase I (R41) and $500,000 for phase II (R42).
For more information about this funding opportunity, please contact NCI SBIR Program Director Ashim Subedee (firstname.lastname@example.org).